Table 1.
Patient characteristics in the three different fractionation cohorts
| Variable | 4F | 3F | 2F | |
|---|---|---|---|---|
| Number of men | 19 | 107 | 103 | |
| Median age (years) | 65 (56-73) | 61 (45-67) | 68 (54-79) | |
| Low-risk PC | 15 (79%) | 85 (79%) | 69 (67%) | |
| Intermediate-risk PC | 4 (21%) | 22 (21%) | 34 (33%) | |
| PSA density | ||||
| < 0.15 | 6 (32%) | 27 (25%) | 25 (24%) | |
| 0.15-0.19 | 4 (21%) | 34 (32%) | 22 (21%) | |
| ≥ 0.20 | 9 (47%) | 46 (43%) | 56 (54%) | |
| Positive biopsies, median number | 1 | 3 | 2 | |
| Positive biopsy length (*), median | 9 | 9 | 8 | |
| Mean pre-treat PSA (µg/lit) | 6.2 (1.5-10) | 6.2 (2-12) | 7.3 (3.3-15) | |
| Mean pre-treat V (cm3) | 33 (20-50) | 32 (14-63) | 34 (15-60) | |
| Median follow-up (years) | 10.2 (6.4-13.0) | 7.1 (2.2-10.3) | 6.1 (1.9-10.8) | |
*
mm, 4F – 4 fractions of 9.5 Gy in 2 days, 3F – 3 fractions of 11 Gy in 4 weeks, 2F – 2 fractions of 14 Gy in 2 weeks , PC – prostate cancer, PSA – prostate specific antigen